Integra LifeSciences to Participate in Investor Conferences in May
PLAINSBORO, N.J., May 7, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will present at the following conferences in the next few weeks:
- At 3:00 PM PT on Tuesday, May 14, 2013, Jack Henneman, Chief Financial Officer of Integra, will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV. The presentation will not be webcast.
- At 2:30 PM ET on Tuesday, May 21, 2013, Mr. Henneman will present at the UBS Global Healthcare Conference in New York, NY. This presentation will not be webcast.
- At 11:20 AM ET on Thursday, May 30, 2013, Mr. Henneman will present at the Deutsche Bank Health Care Conference in Boston, MA. This presentation will not be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com
Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III
Corporate Vice President,
Finance and Administration
and Chief Financial Officer
(609) 275-0500
Investor Relations:
Angela Steinway
(609) 936-2268
angela.steinway@integralife.com